Role of EGF Pathway in Regulating Bronchial Carcinoid Cell Proliferation Abstract #680

Introduction: Bronchial carcinoids (BC) are rare neuroendocrine tumors. Surgery is not feasible for infiltrating and metastatic disease. Medical therapy is often tried but is represented by chemotherapy and radiation, while somatostatin analogues are employed for symptomatic control. It is necessary to identify new molecules capable of providing medical treatment in cases for which surgical removal is not feasible. EGF, TGFα are growth factors which were demonstrated to be important in neuroendocrine tumors. EGF and TGFα bind to the EGF receptor and lead to the transcription of genes that regulate cell proliferation.
Aim(s): To evaluate the effects of Sunitinib, a multi-targeted receptor tyrosine kinase (RTK) inhibitor, and NVP-BEZ235, a PI3K/mTOR inhibitor alone or in combination with EGF, on primary BC cell cultures, to verify the involvement of EGF pathway in regulating crucial cellular processes.
Materials and methods: BC primary cultures were treated with Sunitinib and NVP-BEZ235 alone or with EGF. We assessed the presence of EGFR in all cell cultures by immunofluorescences, and found that EGFR is present in all samples analysed.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Teresa Gagliano
Keywords: EGF, EGFR, BC

To read results and conclusion, please login ...

Further abstracts you may be interested in

#933 The Cytotoxic Effect of Sunitinib on Human Bronchial Carcinoid Cell Lines and Primary Cultures is Counteracted by EGF and IGF-1, but not by VEGF
Introduction: Bronchial carcinoids (BC) are rare tumors originating from endocrine cells dispersed in the respiratory epithelium. The main BC treatment is surgery, but which is not feasible for large, infiltrating and metastatic disease. In these settings, medical therapy is often tried. Therefore it is important to identify new therapeutic targets and new molecules capable of providing adequate medical treatment for patients with BC. Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase inhibitor.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Teresa Gagliano
Keywords: BC, RTK, Sunitinib
#1039 Receptor Tyrosine-Kinases Inhibition: New Insights on Therapeutic Implications of EGFR and IGF1R in Human Bronchopulmonary NET
Introduction: The main treatment for bronchopulmonary NET(BP-NET) is surgery, which is not feasible for infiltrating and metastatic disease, where medical therapy is tried. Identifying new therapeutic targets is important to provide adequate medical treatment for patients with BP-NET. Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor (TKI), is mainly described to inhibit VEGF
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Teresa Gagliano
Keywords: RTK, BP-NET, IGF1R, EGFR
#1462 Cross-Talk Between EGFR and IGF1R Influences the Response to RTK Inhibitors in Bronchopulmonary (BP)-NET Cell Lines
Introduction: BP-NETs represent ~30% of all neuroendocrine tumors. BP-NET treatment is challenging due to onset of resistance to chemo and targeted therapies. EGFR and IGF1R had been associated with tumor onset and progression in several neoplasia.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Teresa Gagliano
Keywords: BP-NET RTK
#1173 Investigation of the Effects of Sunitinib on Pheochromocytoma and Paraganglioma Primary Cultures
Introduction: The main treatment for Pheochromocytoma and Paraganglioma is surgery. However these tumors are highly vascularized, suggesting the possible role for anti-angiogenic agents in the medical therapy. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor (TKI), mainly described to inhibit VEGFR
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Teresa Gagliano
Authors: Bellio M, Gagliano T, Feo C, Balboni F, ...
#1090 p27kip1 Is Involved in the Resistance of Human Bronchial Carcinoids to m-TOR Inhibitors
Introduction: Bronchial carcinoids (BC) are still orphan of medical therapy. We previously demonstrated that the typical BC human cell line NCI-H727 is sensitive to Everolimus (E), in terms of cell viability reduction, with a G0 cell-cycle arrest, while the atypical human BC cell line NCI-H720 is not. The mechanisms underlying this phenomenon have not been clarified
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Master Degree Katiuscia Benfini
Keywords: RAD001, BC, p27kip1, Cell cycle